Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. - Wikidata - wikimedia - TriplyDB

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q47450132

about

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Intraoperative Molecular Imaging in Lung Cancer: The State of the Art and the Future.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?The importance of the initial response to cancer treatment in predicting longer overall survival.Third generation EGFR TKIs: current data and future directions.Mechanisms of receptor tyrosine kinase activation in cancer.Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.Osimertinib in first-line treatment-is a comparison not proof?Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.Afatinib in advanced NSCLC: a profile of its use.[Advances in Antiangiogenic Treatment of Advanced Non-squamous Non-small Cell Lung Cancer in 2017 ASCO and WCLC].First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients.First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.Expanding role for radiotherapy in metastatic non-small cell lung cancer in the era of targeted therapy and immuno-oncology.Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.Osimertinib, the winner, but cannot yet take it all.Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome.The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine.Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.EGFR targeted therapy for lung cancer: are we almost there?Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

P2860

Q49300205-663FD0C0-2DAD-4F12-8986-5105A0B35DEF Q49341132-C67057E3-9FCB-4B31-BA1B-C08CFEE855ED Q49582344-6CD687F1-C79F-46A1-8C86-B97702C95004 Q49685856-ABF7C7A0-599A-4B1A-978B-AC40BC592CEB Q49887956-D086254B-E628-4595-90A5-962C6D7431D8 Q49888000-7C29238E-89F1-4A71-A10E-74CD59EDED84 Q50056486-AEB252C9-5C48-4B71-9E81-E99C295730D1 Q50073382-5D0949D2-5A8A-4238-999E-347F2EE4A057 Q51741619-A39589FE-E3AD-4C58-B18D-BF5553CAE76F Q52318443-1771D393-70D9-454C-B360-063EA64FBF43 Q52559905-66BDE6CE-B961-4A07-A1BD-698373B54387 Q52591096-2672B9C4-0476-449F-82A0-8F49DF6A3836 Q52610737-FD797C05-263D-4FCB-A801-FF2022F70FB3 Q52621968-C4B7CE76-8F29-4882-B5E9-D8B50C8CB38C Q52642806-9D6833CC-A0C1-4B44-B31D-023D898B74A9 Q52645038-A14718A6-8213-49F5-8A7C-963C35E7B120 Q52655265-EC712967-7E66-4340-A7B2-F7B039C1A715 Q54109655-F0B75B0E-62DD-4AD2-A9B5-7FAF6F030F28 Q54110124-22C4AD87-5F69-4A64-9779-CCE17A9F1708 Q54939982-BAFDD856-D273-4035-BC49-729475F08839 Q54958056-6AA5064D-EDCF-4541-9707-A1FF5CBC719E Q54959395-F84206B0-8E9F-4DF6-8CA2-AF88D0C7785B Q54976886-F7DFC62D-B770-4DCE-9E81-59BA07ED6F3E Q54977541-7B532AF8-E716-4150-BB83-A82F67058169 Q54978827-2F3FBB21-E064-49C1-9D86-80951ADA9599 Q54982227-89831D79-6D41-4DEB-BEA1-1172CDAA3889 Q54995746-CB749C51-6A81-44C6-A9C8-16A6B2B1CA46 Q55082628-483FABD2-758E-41A7-A810-ED6ADB9D54E5 Q55095898-39EB5E3C-D673-4385-96C7-03CCD3945FC5 Q55172706-41E31E20-E4F9-4D36-8BAF-8B301A26D016 Q55189638-FCEA3292-1BB9-4AAF-8446-3300FB7E950F Q55226999-E6292577-1DC1-4621-9C9F-1C3818793640 Q55227741-2E9E587D-9FA4-419F-9B85-4EED300CF748 Q55261985-A8FA2BCA-8F0A-4B38-855A-3991800877D2 Q55343368-4D0CC353-E262-4252-AD77-20DBB89D795B Q55368437-993188AD-3089-4A7A-B3A6-62DFB2CE51F2 Q55383949-4DAD3A16-00F4-4F8B-B5AE-F693CB6644D2 Q55401599-50F4F7BC-509F-47A1-B9C6-BA05B374BD05 Q55405362-DB7CD115-294A-4DE2-A9C4-A1694A093CDF Q55417125-BCC4C72A-D4B4-42A8-9498-A4371C4028C9

P2860

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q47450132

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@en

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@nl

type

label

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@en

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@nl

prefLabel

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@en

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@nl

P1433

Q47450132-D651F01B-2B7F-4223-B0D7-B2877603FE4F

P1476

Q47450132-478BE31B-3548-4C78-B0F9-4926A3242134

P2093

Q47450132-0644C14C-1E58-4B10-B034-117F5D3560BF

Q47450132-0F22F1CC-9DA2-47A3-B4BA-9BA763727842

Q47450132-0FBA6B5D-2A1E-47E3-B5F9-31C1BEF4D029

Q47450132-1B191361-6968-4478-A66E-850480B3A68B

Q47450132-1E594F51-25C9-413A-811D-940ED1A697A2

Q47450132-22F5EECF-5939-48AA-9016-32E285EB8EE3

Q47450132-353F4343-11AC-440A-A957-12981545EF93

Q47450132-388423E8-85FB-4ADB-B8CA-791DA6274336

Q47450132-4D1BC37E-BD96-4D52-8843-0D9918EFFB6D

Q47450132-5021F218-B9E4-4A03-950F-B5A10AE3FCFF

P304

Q47450132-5746809C-A4D0-409E-B354-69A8FFA46C68

P31

Q47450132-A3EF1AA5-7676-4BBE-8F94-0CA8362D0334

P356

Q47450132-C5F3633E-CB6D-4F39-8828-DA9444739551

P407

Q47450132-B73D0ECE-705E-4613-B459-3B1FA12FBAC9

P433

Q47450132-42004069-A177-424B-A56B-329CD5EB0BC1

P478

Q47450132-24976CBF-A2D2-46FA-9D45-0A5CE3C25512

P50

Q47450132-A0E5A283-1C34-4F08-8C38-E8275AE72E98

Q47450132-CAABA26F-2E7D-4842-9946-50A8A6FE9F08

Q47450132-EE70FBD6-BDF4-4BFD-85CB-B04627FD8F24

P577

Q47450132-9474A39E-1F97-4224-AE7A-9E2FF8D08101

P698

Q47450132-9CCC29D1-DC91-4E94-B8D6-9E219AC22D45

P921

Q47450132-2F8EAB93-6AF6-427A-B284-6EFA7FACAD1A

P356

P1433

The New England Journal of Medicine

P1476

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

@en

P2093

Arunee Dechaphunkul

http://www.w3.org/2001/XMLSchema#string

Busyamas Chewaskulyong

http://www.w3.org/2001/XMLSchema#string

Byoung Chul Cho

http://www.w3.org/2001/XMLSchema#string

Caicun Zhou

http://www.w3.org/2001/XMLSchema#string

David Planchard

http://www.w3.org/2001/XMLSchema#string

Eun Kyung Cho

http://www.w3.org/2001/XMLSchema#string

FLAURA Investigators

http://www.w3.org/2001/XMLSchema#string

Fumio Imamura

http://www.w3.org/2001/XMLSchema#string

Isamu Okamoto

http://www.w3.org/2001/XMLSchema#string

Jhanelle E Gray

http://www.w3.org/2001/XMLSchema#string

P304

113-125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1713137

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

378

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Soria

P577

2017-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29151359

http://www.w3.org/2001/XMLSchema#string

P921